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ABSTRACT
Background Ethnic disparities in cancer survival have
been documented in many populations and cancer types.
The causes of these inequalities are not well understood
but may include disease and patient characteristics,
treatment differences and health service factors. Survival
was compared in a cohort of Maori (Indigenous) and non-
Maori New Zealanders with colon cancer, and the
contribution of demographics, disease characteristics,
patient comorbidity, treatment and healthcare factors to
survival disparities was assessed.
Methods Maori patients diagnosed as having colon
cancer between 1996 and 2003 were identified from the
New Zealand Cancer Registry and compared with
a randomly selected sample of non-Maori patients.
Clinical and outcome data were obtained from medical
records, pathology reports and the national mortality
database. Cancer-specific survival was examined using
KaplaneMeier survival curves and Cox hazards modelling
with multivariable adjustment.
Results 301 Maori and 328 non-Maori patients with
colon cancer were compared. Maori had a significantly
poorer cancer survival than non-Maori (hazard ratio
(HR)¼1.33, 95% CI 1.03 to 1.71) that was not explained
by demographic or disease characteristics. The most
important factors contributing to poorer survival in Maori
were patient comorbidity and markers of healthcare
access, each of which accounted for around a third of the
survival disparity. The final model accounted for almost all
the survival disparity between Maori and non-Maori
patients (HR¼1.07, 95% CI 0.77 to 1.47).
Conclusion Higher patient comorbidity and poorer
access and quality of cancer care are both important
explanations for worse survival in Maori compared with
non-Maori New Zealanders with colon cancer.
INTRODUCTION
Ethnic disparities in cancer survival have been
described in many populations and cancer types.
Survival disparities are found between Indigenous
and non-Indigenous peoples in New Zealand,1e3
Australia4 5 and the USA,6e8 and between ethnic
minority and majority populations in many
countries, particularly the USA.6 9 10 Survival
differences are seen across a range of cancer sites
including malignancies of the breast, prostate, lung
and colon. 6 9 10
Cancer is an important and growing contributor
to the 8e9-year difference in life expectancy
betweenMaori and non-Maori New Zealanders.11 12
Maori are the Indigenous peoples of New Zealand
and make up 15% of the 4 million population; the
non-Indigenous population is predominantly
European in origin with signiﬁcant Paciﬁc (7%) and
Asian (9%) groupings.13 As with many kinds of
cancer, Maori patients have a poorer survival from
colon cancer compared with non-Maori.1 2 New
Zealand has a particularly high incidence and
mortality from colorectal cancer.14 Age-adjusted
incidence is lower in Maori compared with non-
Maori populations (nine compared with 15 per
100 000),2 but mortalities are now similar, having
decreased in non-Maori and increased in Maori over
time.11 15 16
The causes of ethnic disparities in cancer survival
are poorly understood but are likely to include
factors at the level of individual patients, healthcare
processes and health systems overall.9 17 18 The
existence of ethnic survival disparities in many
populations and cancer types suggests that these
factors are at work across a range of different
contexts and ethnic groupings.
Patient-level factors that may affect survival
include tumour characteristics (grade and stage at
diagnosis) and comorbid conditions. Late-stage
diagnosis contributes to cancer survival disparities
between Maori and non-Maori New Zealanders,1 2
Indigenous and non-Indigenous Australians,4 and
Black and White Americans19e21 but is unlikely to
explain the majority of ethnic survival disparities.
Fewer studies have assessed the impact of patient
cormorbidity (which is difﬁcult to measure accu-
rately from administrative data), although a higher
comorbidity contributes to survival disparities
between Indigenous and non-Indigenous
Australians.4 There is some evidence that biological
factors play a role in survival disparities for breast
cancer22 but not for colon cancer.20 23
Health systemfactorsmay impact bothat the level
of treatment decisions and processes and at more
structural levels such as the location, resourcing and
accessibility of healthcare facilities. Lower rates of
cancer treatment (including surgery and chemo-
therapy) contribute to Indigenous/non-Indigenous
survival disparities in Australia4 and ethnic survival
disparities in the USA.9 19 24e26 Differential health-
care access and institutional factors receive partic-
ular emphasis in the USA context27 28 but do not
fully explain survival inequalities, since these are
found even in equal-access healthcare settings.9 19
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New Zealand has a publicly funded national health system
that provides specialist and hospital care to all residents without
patient charges. There are no existing New Zealand data on the
role of health systems factors in cancer survival disparities, but
Maori/non-Maori inequalities are found in management of other
diseases with Maori receiving fewer health services relative to
expected need29e31 and lower quality care in some contexts.32
Maori are more likely to self-report experiences of being
discriminated against by a health professional due to their
ethnicity,33 which may contribute to suboptimal treatment.
Higher rates of socio-economic disadvantage in the Maori
population make it harder for many Maori patients to access
services requiring copayments such as primary healthcare and
prescription medication.31 34
Our study examined survival disparities between Maori and
non-Maori patients with a ﬁrst-time diagnosis of colon cancer.
We assessed the relative contribution of patient, treatment and
health systems factors to survival disparities, adjusting for
patient-level factors ﬁrst in order to assess the role of treatment
and health service differences independent of clinical factors.
Our study cohort was drawn from the entire country and
included individual review of medical notes from both public
and private health facilities, allowing a comprehensive compar-
ison of factors contributing to colon cancer survival disparities at
a national level.
METHODS
New Zealand residents diagnosed as having colon cancer
between 1996 and 2003 were eligible for study inclusion. Cases
came from patients notiﬁed to the New Zealand Cancer
Registry with a primary tumour in the colon (ICD-10-AM site
codes C18.0 to 19.0 excluding 18.1) and morphology consistent
with adenocarcinoma. (New Zealand has mandatory registra-
tion of all primary cancers except non-melanoma skin cancers
and carcinoma in situ.) Patients were ineligible if they were less
than 25 years at diagnosis, were normally resident outside New
Zealand, had a previous diagnosis of colon cancer, had no histo-
logical diagnosis or were diagnosed after death.
All Maori patients meeting the above criteria were included
along with an approximately equal number of randomly
sampled non-Maori patients. Patients were classiﬁed as Maori if
their ethnicity was recorded as such in any of the three cancer
registry ethnicity ﬁelds. (These ﬁelds are based on self-identiﬁed
ethnicity data from hospital admission and registration sheets.)
Patients whose ethnicity was not recorded in the cancer registry
were classiﬁed as non-Maori.35
Clinical data were abstracted from patients’ medical records,
including public and private healthcare providers. Pathology
reports were obtained for all patients from their healthcare records,
the cancer registry or directly from the reporting laboratory. Data
were recorded on a standardised form by a physician (SH) and
double-entered into an electronic database. Data included details of
patients’ presentation, investigation for diagnosis of colon cancer,
comorbid conditions present at the time of diagnosis, smoking
status, tumour characteristics (including location, histological
features and stage at diagnosis), surgical treatment and adjuvant
treatment (including chemotherapy and radiotherapy). Small area
deprivation and rurality were assigned according to each patient’s
domicile (census area) code at the time of diagnosis. Small area
deprivation was classiﬁed by the New Zealand deprivation index,
an area-based index calculated from aggregated census data on
residents’ socio-economic characteristics (such as car access,
housing tenure and beneﬁt receipt).36 Outcome data (vital status
and cause of death) were obtained by linking study patients to the
national mortality database, with follow-up to the end of 2005.
Patients whose deaths were not recorded in the mortality database
were assumed to be still alive at the end of follow-up, while those
who died from causes other than colon cancer were censored at the
date of death.
Maori and non-Maori cohorts were compared for demo-
graphics, tumour characteristics, patient comorbidity
and smoking, treatment and markers of health service access.
Maori/non-Maori prevalence ratios were adjusted for age, sex
and year of diagnosis using log Poisson regression with robust
variance estimation.37 Cancer-speciﬁc survival curves for Maori
and non-Maori were estimated using the KaplaneMeier method
and compared by logrank test. Mortality hazards were compared
using Cox regression modelling.
Hazard ratios were sequentially adjusted for ﬁve domains of
covariates to assess the relative contribution of each domain to
Maori/non-Maori survival disparities. These domains were:
patient demographics (age, sex and year of diagnosis), disease
characteristics (stage, grade and site of tumour, and emergency
presentation), patient comorbidity (speciﬁc comorbid conditions
and smoking), treatment (deﬁnitive surgery, surgeon type, delay
to surgery and adjuvant chemotherapy) and markers of health-
care access (treatment facility type, small area deprivation and
rurality). We used the Hausman test to assess the signiﬁcance of
a change in hazard ratio with adjustment for each domain.38 39
Speciﬁc comorbid conditions were included as covariates in
survival analyses if they were found to be independently asso-
ciated with colon cancer survival in the study cohort.40 These
conditions were: previous myocardial infarction, previous or
current heart failure, current respiratory disease, diabetes
mellitus, cerebrovascular disease, renal disease and neurological
disorders. For the purpose of survival analyses, small area depri-
vation was conceptualised as a marker of healthcare access
(rather than an individual sociodemographic variable). This
reﬂects the inﬂuence of deprivation on cancer survival indepen-
dent of individual characteristics such as stage at diagnosis,
comorbidity or smoking (which were adjusted for prior to
including deprivation in the model).41 42
Approval for this study was granted by the New Zealand
Multi-Region Ethics Committee (MEC/05/06/069). All analyses
were carried out in SAS (version 9.1, SAS Institute, Cary, North
Carolina).
RESULTS
A total of 376 Maori patients met the study criteria based on
cancer registry records, and a further 400 non-Maori patients
were randomly selected from the registry as a comparison
cohort. Ninety one (12%) of those sampled were later excluded
because further information showed they were ineligible for
study inclusion (65 had miscoded data (primarily cancer site) in
the cancer registry, and a further 26 had no histological diag-
nosis), giving 329 Maori and 356 non-Maori patients. Full data
were obtained for 301 Maori and 328 non-Maori patients (92%
of the eligible sample). Based on cancer registry records, 93% of
the non-Maori cohort were of European ethnicity.
The Maori cohort was signiﬁcantly younger than the non-
Maori cohort (Table 1) in keeping with the younger age structure
of the total Maori population in New Zealand.12 Maori patients
had a higher prevalence of comorbid conditions, with around two
and a half times the rates of diabetes, heart failure, respiratory
disease and renal disease seen in non-Maori. Maori patients were
about 50% more likely to be smokers.
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Compared with non-Maori patients, Maori were more likely
to be diagnosed as having advanced (metastatic) cancer and less
likely to be diagnosed as having localised disease, although
differences were non-signiﬁcant after adjustment for age and
sex. The stage distribution of the study cohort was not signiﬁ-
cantly different to that of all registered colon cancers from the
corresponding period, except that the study cohort had a lower
prevalence of unstaged cancer (4.5% overall compared with
7.4% in the Cancer Registry, p¼0.003). Maori patients were
more likely to have left-sided tumours, while non-Maori had
more right-sided tumours. Cancers inMaori patients tended to be
less aggressive with a higher proportion of well-differentiated
tumours. Maori patients were signiﬁcantly more likely to present
to hospital services as an emergency case (with bowel obstruc-
tion, for example) rather than being electively referred by
a primary care physician.
Non-Maori patients were signiﬁcantly more likely than Maori
to undergo deﬁnitive surgery (that is, complete removal of the
primary tumour either at colonoscopy or at operation) (Table 2).
No signiﬁcant differences were found in the type of surgeon
performing the operation, but Maori patients were (non-signiﬁ-
cantly) more likely to experience a delay of a month or more
between diagnosis and treatment. Maori patients were signiﬁ-
cantly less likely to receive adjuvant chemotherapy.
The cohorts differed signiﬁcantly in indicators of health
service access. Maori patients were more likely to be treated
in secondary (smaller) public healthcare facilities and less
likely to be treated in private facilities. They were also more
likely to live in high-deprivation areas and were almost four
times as likely to live in rural areas compared with non-Maori
patients.
Table 1 Demographics, tumour characteristics, comorbid conditions
and smoking status in Maori and non-Maori cohorts
Maori
(n[301)
Non-Maori
(n[356)
Prevalence ratio
(95% CI)* p Value
Age at diagnosis (mean) 61.3 years 70.6 years <0.0001
Female 43.9% 52.4% 0.03
Tumour stage
Stage I and II 40.9% 44.8% 1.01 (0.83 to 1.23) 0.9
Stage III (+ve nodes) 28.9% 34.2% 0.84 (0.65 to 1.08) 0.2
Stage IV (metastases) 28.9% 20.1% 1.20 (0.89 to 1.62) 0.2
Unstaged 1.3% 0.9% 2.33 (0.91 to 5.97) 0.08
Tumour site
Right colon 35.9% 46.7% 0.81 (0.66 to 0.99) 0.04
Left colon 44.9% 29.6% 1.37 (1.09 to 1.72) 0.007
Rectosigmoid 16.0% 16.2% 1.09 (0.74 to 1.61) 0.7
Synchronous 3.3% 7.6% 0.46 (0.20 to 1.05) 0.06
Tumour grade
Well differentiated 12.0% 7.6% 1.97 (1.17 to 3.33) 0.01
Moderately
differentiated
71.1% 73.5% 0.93 (0.84 to 1.04) 0.2
Poorly differentiated 16.9% 18.9% 0.91 (0.63 to 1.32) 0.6
Emergency presentation 38.2% 26.5% 1.44 (1.13 to 1.84) 0.004
Comorbid conditions
Previous
myocardial infarction
8.0% 8.2% 1.22 (0.68 to 2.19) 0.5
Heart failure 11.6% 9.2% 2.65 (1.63 to 4.32) <0.0001
Diabetes 20.9% 10.7% 2.46 (1.66 to 3.65) <0.0001
Respiratory disease 7.0% 3.7% 2.42 (1.18 to 5.00) 0. 02
Cerebrovascular
disease
6.6% 9.2% 1.25 (0.69 to 2.26) 0.5
Renal disease 6.6% 4.0% 2.60 (1.27 to 5.32) 0.01
Neurological disordery 5.3% 7.6% 0.71 (0.36 to 1.40) 0.3
Smoking status
Current smoker 27.9% 12.2% 1.54 (1.07 to 2.23) 0.02
Ex-smoker 38.5% 36.0% 1.20 (0.97 to 1.49) 0.09
Non-smoker 29.6% 45.4% 0.72 (0.57 to 0.90) 0.005
Missing 4.0% 6.4% 0.64 (0.31 to 1.33) 0.2
*Prevalence ratios are adjusted for age, sex and year of diagnosis using log Poisson
regression with robust convergence estimation.
ySignificant neurological and psychiatric disorders other than cerebrovascular
diseasedthat is, bipolar disorder, blindness, dementia, epilepsy, idiopathic peripheral
neuropathy, intellectual impairment, multiple sclerosis, Parkinson disease, polio, previous
head injury, schizophrenia and spinal stenosis.
Table 2 Treatment and markers of health service access in Maori and
non-Maori cohorts
Maori
(n[301)
Non-Maori
(n[356)
Prevalence
ratio (95% CI)* p Value
Definitive surgeryy 87.7 93.6 0.93 (0.88 to 0.98) 0.01
Surgeon type
Colorectal surgeon 14.3 15.6 0.70 (0.47 to 1.05) 0.09
General surgeon 72.1 72.9 1.02 (0.92 to 1.13) 0.7
Surgical trainee 8.6 6.7 1.37 (0.76 to 2.49) 0.3
Delay to surgery
(>28 days)
14.3 11.9 1.40 (0.90 to 2.20) 0.1
Adjuvant chemotherapy 18.9 19.8 0.61 (0.42 to 0.86) 0.006
Treatment facility
Public secondary 61.1 46.3 1.40 (1.20 to 1.65) <0.0001
Public tertiary 29.2 33.2 0.89 (0.69 to 1.14) 0.4
Private 5.0 17.7 0.19 (0.11 to 0.32) <0.0001
Small-area deprivation
1 (least deprived) 6.3 14.3 0.37 (0.22 to 0.62) 0.0002
2 7.3 19.2 0.34 (0.21 to 0.56) <0.0001
3 16.0 22.0 0.81 (0.57 to 1.16) 0.2
4 27.2 26.5 1.06 (0.80 to 1.41) 0.7
5 (most deprived) 43.2 18.0 2.41 (1.82 to 3.19) <0.0001
Rurality
Urban 77.4 90.0 0.86 (0.79 to 0.93) 0.0001
Semirural 6.6 4.9 1.20 (0.59 to 2.41) 0.6
Rural 16.0 4.3 3.82 (2.00 to 7.29) <0.0001
*Prevalence ratios are adjusted for age, sex and year of diagnosis using log Poisson
regression with robust convergence estimation.
yDefinitive surgery: surgical removal of tumour (including complete excision during
colonoscopy).
Figure 1 Cancer-specific survival for Maori and non-Maori cohorts
(unadjusted).
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Maori had a lower cancer-speciﬁc survival than non-Maori
patients (Figure 1). The crude 5-year cancer-speciﬁc survival was
61.1% in non-Maori and 52.5% in Maori patients. The crude
mortality hazard ratio for Maori compared with non-Maori
patients was 1.33 (95% CI 1.03 to 1.71) (Table 3). This disparity
persisted with adjustment for demographic factors (hazard
ratio¼1.30 after adjustment for age, sex and year of diagnosis)
and disease factors (hazard ratio¼1.33 after further adjustment
for stage, grade and site of tumour, and emergency presentation).
Patient comorbidity accounted for around a third of the
Maori/non-Maori disparity in cancer survival, with adjustment
for speciﬁc comorbid conditions and patient smoking reducing
the hazard ratio from 1.33 to 1.20 (Table 3). Differences in
treatment for Maori and non-Maori patients may have contrib-
uted to the survival disparity, with a (non-signiﬁcant) reduction
in the hazard ratio from 1.20 to 1.17 following further adjust-
ment for deﬁnitive surgery, surgeon type, delay to surgery and
receipt of adjuvant chemotherapy. Differences in indicators of
healthcare access contributed signiﬁcantly to the survival
disparity, with the hazard ratio falling from 1.17 to 1.07 with
further adjustment for treatment facility type, small area
deprivation and rurality of patient’s residence.
Factors included in this ﬁnal model (Table 4) together
accounted for almost all the Maori/non-Maori disparity in cancer
survival, with Maori patients only 7% more likely to die from
their colon cancer after adjustment for demographics, tumour
characteristics, patient comorbidity, treatment and markers of
health service access.
DISCUSSION
In a population-based cohort of New Zealanders with colon
cancer, Maori patients had a poorer survival than non-Maori,
with around a 30% higher risk of dying from their cancer. This
survival disparity was not due to disease characteristics: Maori
patients generally had lower-grade tumours and were not
signiﬁcantly more likely to present with advanced disease.
Higher rates of pre-existing medical conditions and more limited
Table 3 Hazard ratios for cancer-specific mortality risk in Maori and
non-Maori cohorts with stepwise adjustment for demographics, disease
factors, patient factors, healthcare processes and healthcare access
Adjusted for:
Additional variables
in model
Hazard
ratio 95% CI
0. Unadjusted e 1.33 1.03 to 1.71
1. Demographics Age, sex, year of diagnosis 1.30 0.99 to 1.71
2. Disease factors +Stage 1.29 0.97 to 1.71
+Grade 1.31 0.99 to 1.74
+Site 1.36 1.01 to 1.82
+Emergency presentation 1.33 0.99 to 1.79
3. Patient factors +Comorbidities* 1.24 0.92 to 1.68
+Smoking 1.20y 0.89 to 1.63
4. Healthcare processes +Definitive surgery 1.21 0.89 to 1.64
+Surgeon type 1.21 0.90 to 1.65
+Delay to surgery 1.20 0.88 to 1.63
+Adjuvant chemotherapy 1.17 0.86 to 1.60
5. Healthcare access +Treatment facility type 1.12 0.82 to 1.53
+Small-area deprivation 1.10 0.80 to 1.52
+Rurality 1.07y 0.77 to 1.47
Hazard ratios calculated using Cox proportional hazards regression with imputed data for 33
individuals with missing smoking status (almost identical results obtained with missing
variable indicator).
*Comorbiditiesdthat is, previous MI, heart failure, respiratory disease, diabetes,
cerebrovascular disease, renal disease and neurological disorders (as outlined in Table 1).
ySignificant decrease in hazard ratio compared with previous domain, that is p value <0.05
by Hausman test.
Table 4 Hazard ratios for selected variables from final model (cancer-
specific mortality risk)
n % HR 95% CI
Indigenous status
Non-Maori 328 52.2 1.00
Maori 301 47.9 1.07 0.77 to 1.47
Stage at diagnosis
Stage I 79 12.6 0.51 0.22 to 1.20
Stage II 191 30.4 1.00
Stage III 199 31.6 3.81 2.36 to 6.16
Stage IV 153 24.3 19.64 12.36 to 31.20
Unstaged 7 1.1 4.26 1.12 to 16.21
Grade (cell differentiation)
Well differentiated 61 9.7 0.77 0.44 to 1.35
Moderately differentiated 455 72.3 1.00
Poorly differentiated 113 18.0 1.45 1.04 to 2.03
Tumour site
Right colon 261 41.5 1.11 0.80 to 1.55
Left colon 232 36.9 1.00
Rectosigmoid junction 101 16.1 0.67 0.44 to 1.00
>1 site (multiple tumours) 35 5.6 1.02 0.57 to 1.82
Emergency presentation
No 427 67.9 1.00
Yes 202 32.1 1.26 0.94 to 1.69
Comorbid conditions
Previous myocardial infarction 51 8.1 1.27 0.76 to 2.11
Heart failure 65 10.3 1.53 0.89 to 2.62
Diabetes 98 15.6 0.95 0.64 to 1.42
Respiratory disease 33 5.3 0.68 0.34 to 1.38
Cerebrovascular disease 50 8.0 1.31 0.81 to 2.12
Renal disease 33 5.3 1.00 0.49 to 2.05
Neurological disorder* 41 6.5 2.01 1.16 to 3.48
Smoking status
Non-smoker 124 19.7 1.00
Current smoker 234 37.2 1.16 0.78 to 1.72
Ex-smoker 238 37.8 1.50 1.08 to 2.10
Definitive surgery
No 66 10.5 1.00
Yes 563 89.5 0.24 0.15 to 0.39
Type of surgeon
General surgeon 456 72.5 1.00
Specialist colorectal surgeon 94 14.9 1.22 0.80 to 1.85
Trainee surgeon 48 7.6 1.13 0.66 to 1.92
Delay to treatment
No 547 87.0 1.00
Yes 82 13.0 1.10 0.72 to 1.70
Adjuvant chemotherapy
No 507 80.6 1.00
Yes 122 19.4 0.55 0.35 to 0.88
Treatment-facility type
Secondary public hospital 336 53.4 1.34 0.97 to 1.84
Tertiary (teaching) public hospital 197 31.3 1.00
Private hospital 73 11.6 0.92 0.53 to 1.58
Small-area deprivation (per 10%
increase in deprivation score)
1.02 0.96 to 1.08
Rurality
Urban 531 84.4 1.00
Semirural 36 5.7 1.24 0.72 to 2.15
Rural 62 9.9 1.21 0.79 to 1.84
Hazard ratios calculated using Cox proportional hazards regression with imputed data for 33
individuals with missing smoking status (almost identical results obtained with a missing
variable indicator).
*Significant neurological and psychiatric disorders other than cerebrovascular diseasedthat
is, bipolar disorder, blindness, dementia, epilepsy, idiopathic peripheral neuropathy,
intellectual impairment, multiple sclerosis, Parkinson disease, polio, previous head injury,
schizophrenia and spinal stenosis.
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health service access each appeared to account for around a third
of the excess mortality risk in Maori patients, while lower rates
of cancer treatment may also have made a modest contribution.
Together these factors accounted for almost all the survival
disparity between Maori and non-Maori patients.
We did not ﬁnd any signiﬁcant Maori/non-Maori differences
in stage at diagnosis, although non-signiﬁcant differences were
consistent with previous evidence of more advanced cancer in
Maori patients.2 New Zealand does not currently have a national
screening programme for colon cancer, but Maori/non-Maori
disparities are evident in access to breast and cervical cancer
screening43 44 and specialist cancer services.45 Inadequate access
to primary and diagnostic health services may also contribute to
higher rates of emergency presentation in Maori patients with
colon cancer.
Maori patients in our cohort tended to have more favourable
tumour characteristics with a higher prevalence of well-
differentiated cancers. Black patients in the USA are likewise
more likely than White patients to have well-differentiated
tumours of the colon,20 23 arguing against the suggestion that
survival disparities reﬂect less favourable biology in ethnic
minority groups. Current evidence does not support a role for
genetic factors in ethnic disparities in cancer survival.
Patient comorbidity and smoking were signiﬁcant mediators
of Maori/non-Maori survival disparities. Higher rates of dia-
betes, cardiovascular and respiratory disease in Maori patients
reﬂect high prevalences in the general Maori population.12 Valery
et al found a similarly high comorbidity in Indigenous
Australians with cancer, although the contribution to survival
disparities is difﬁcult to assess (the authors controlled for
comorbidity only after adjusting for treatment differences).4 The
reasons for higher comorbidity and smoking rates in Indigenous
peoples are complex and include greater socio-economic depri-
vation, poorer access to favourable determinants of health and
(ultimately) historical disadvantage through the processes of
colonisation.12 46
Differences in healthcare access and quality are important
mediators of survival disparities between Maori and non-Maori
patients with cancer. Similar disparities exist in cardiac care,
with Maori patients more commonly admitted to hospitals
lacking cardiac intervention services47 contributing to lower
rates of revascularisation compared with non-Maori.29 30 Our
study found several markers of poorer healthcare access in Maori
patients with cancer, who were more likely to live in rural and
economically deprived areas and less likely to receive treatment in
specialist cancer centres or private hospitals. These markers
almost certainly overlap with healthcare quality, which was not
directly assessed. Differential healthcare access has been shown
to contribute to health disparities in other countries.27 28 48 US
hospitals serving predominantly AfricaneAmerican communi-
ties have a more limited capacity and struggle to meet treatment
standardsda de facto segregation of health services that
contributes to poorer health outcomes in the Black population.49
Even if individual facilities in New Zealand provide equitable
care, the structure of the health system as a whole may result in
unequal care for Maori and non-Maori patients, a form of insti-
tutional racism and an important cause of survival disparities.
New Zealand has a public health system that aims to provide
equal-access care to all residents, although individuals may
purchase private health insurance or pay directly to access some
services (including specialist assessment and surgery) through
private health providers. Health insurance coverage is much
lower in the Maori population (Stillman S and Cumming J,
personal communication) as reﬂected here by low rates of
private hospital treatment among Maori patients. Patients with
access to private healthcare may gain a survival beneﬁt from
shorter waiting times and easier access to diagnostic and
treatment services.
In the New Zealand context, socio-economic position is
strongly correlated with ethnicity and is an important mediator
in the relationship between ethnicity and health.11 12 Our only
socio-economic measure was residential area deprivation at the
time of diagnosis. In this study, we view area deprivation as
a marker of health service access more than individual patient
demographics. Many studies show that socio-economic depri-
vation is a predictor of poorer cancer survival primarily through
its effect on stage at diagnosis and cancer treatment.21 41 42 Our
multivariable models examined the effects of individual-level
factors (such as stage at diagnosis and comorbidity) before
contextual factors (such as healthcare access). Having already
adjusted for stage and treatment differences, the remaining effect
of area deprivation is likely to occur primarily through its inﬂu-
ence on healthcare access (including both contextual effects and
patients’ ability to reach and navigate cancer services).
Potential limitations of our study include modest sample
size, misclassiﬁed deaths and possible selection effects. The
relatively low occurrence of colon cancer in the Maori popula-
tion during an 8-year window limits our power to demonstrate
small Maori/non-Maori differences and changes in the hazard
ratio with covariate adjustment. Misclassiﬁcation of the fact of
death is likely to be very small, since all study members were
New Zealand residents, and deaths occurring in New Zealand
are recorded in the national mortality database. A more likely
source of bias is misclassiﬁcation of non-cancer deaths as due to
colon cancer; this would tend to bias Maori/non-Maori hazard
ratios towards the null, since a greater proportion of non-Maori
deaths are due to causes other than colon cancer. Our sample
may represent a slightly selected group of patients, since
inclusion required histological evidence of adenocarcinoma,
excluding just under 7% of all registered cases. This restriction
increased the internal validity of our study, however, and
allowed us to assess the role of tumour biology in survival
disparities.
Strengths of our study include its population-based sample
frame, near-complete data ascertainment (92% of eligible cases)
and comprehensive data collection including detailed comor-
bidity and pathology assessment from review of individual
medical records. Since cohort members and data were drawn
from throughout New Zealand, these ﬁndings inform our
understanding of Indigenous/non-Indigenous disparities at
a national level, including the role played by health service
access and quality. This is highly relevant given the substantial
Maori/non-Maori differences that exist in geographical and
socio-economic distribution, private health insurance and access
to tertiary hospitals.
What is already known on this subject
< Ethnic disparities in cancer survival are observed in many
populations and cancer types.
< Maori (Indigenous) New Zealanders with colon cancer have
poorer survival than patients from other ethnic groups, even
after adjustment for stage at diagnosis.
< Ethnic disparities in cancer survival may reflect differences in
healthcare access and quality.
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Attention to health services is a key step in improving cancer
care and decreasing disparities in cancer outcomes. Potential
strategies to improve access for Maori patients include
development and support of Maori health providers, improving
the cultural accessibility and competence of mainstream
providers and ensuring adequate resources for health services
serving area with large Maori populations.44 45 Finally, ongoing
monitoring of treatment and outcomes by ethnicity provides
important feedback to improve services and help ensure Indige-
nous and non-Indigenous New Zealanders receive an equal
standard of care.
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